Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LIGAND PHARMACEUTICALS INCORPORATED

(LGND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ligand Pharmaceuticals Incorporated : September Investor Roadshow

09/09/2021 | 05:12am EDT

NON-DEAL ROADSHOW

SEPTEMBER 2021

Nasdaq: LGND

SAFE HARBOR STATEMENT

The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it's partners' judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "projects," "could," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, expectations regarding research and development programs, the timing of the initiation or compilation of preclinical studies and clinical trials by Ligand and its partners, expectations regarding product approvals and potential for future revenue growth, and launches by Ligand or its partners and the timing thereof, total addressable market for antibodies. Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherit in Ligand's business, including the inherit risks of clinical development and regulatory approval of product candidates, including that FDA or foreign regulatory authorities may not agree with our or our partners' conclusions regarding the results of clinical trials; Ligand may be unable to successfully integrate operations from acquired businesses or may face other difficulties as a result of acquisitions such as strain on operational resources; the total addressable market for antibodies or other therapeutics may be smaller than estimated; we face competition with respect to our technology platforms, including OmniAb, which may demonstrate greater market acceptance or superiority; partnered commercial products may not perform as expected; Ligand relies on collaborative partners for milestone and royalty payments, royalties, materials revenue, contract payments and other revenue projections; Ligand does not have contractual relationships with certain parties identified as partners and is dependent on WuXi Biologics Ireland Limited to enforce any contractual rights such as payment of royalties or milestones; the possibility that Ligand's and its partners' drug candidates might not be proved to be safe and efficacious and uncertainty regarding the commercial performance of Ligand's and/or its partners' products; and other risks and uncertainties described in its public filings with the Securities and Exchange Commission, available at www.sec.gov. Additional risks may apply to forward-looking statements made in this presentation. Information regarding partnered products and programs comes from information publicly released by our partners. This presentation describes the typical roles and responsibilities of Ligand and our partners and is not intended to be a complete description in all cases. Our trademarks, trade names and service marks referenced herein include Ligand, Captisol, Pelican Expression Technology, OmniAb, OmniChicken, OmniRat, OmniMouse, OmniFlic, OmniClic and OmniTaur . Each other trademark, trade name or service mark appearing in this presentation belongs to its owner.

The process for reconciliation between the non-GAAP adjusted financial numbers presented on slide 12 and the corresponding GAAP figures is shown in the earnings press release for the second quarter ended June 30, 2021 available at https://investor.ligand.com/press-releases. However, other than with respect to total revenues, the Company only provides financial guidance on an adjusted basis and does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Ligand disclaims responsibility for any statement by a person other than its employees and the views expressed by persons other than Ligand employees do not necessarily reflect the views of Ligand.

Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Ligand undertakes no obligation to revise or update this presentation to reflect events or circumstances or update third party research numbers after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

ABOUT LIGAND

3

Medical research and technology

Robust platform of

company discovering medicines,

discovery tools and

improving safety and reducing

technologies needed to

manufacturing costs

solve industry challenges

PEOPLE &

TECHNOLOGY

INNOVATION

INNOVATION

DRIVING

VALUE

Superior support and engagement with pharmaceutical partners for a wide range of medical and health needs

High growth and strong cash flow driven by diverse and growing portfolio of partnerships

PARTNERSFINANCIALS

LIGAND ADDS VALUE . . .

. . . JUST ASK OUR MORE THAN 130 PARTNERS

Our research and technology help partners…

Discover medicines

Improve safety

Reduce costs

4

Ligand's technology

and R&D support entitles us to share in revenue of partners through royalties

PARTNERED PIPELINE

5

BROAD PORTFOLIO WITH OVER 130 DIFFERENT PARTNERS

PROPRIETARY

COMPOUNDS &

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Ligand Pharmaceuticals Inc. published this content on 09 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2021 09:11:05 UTC.


ę Publicnow 2021
All news about LIGAND PHARMACEUTICALS INCORPORATED
09/22LIGAND PHARMACEUTICALS INCORPORATED : Barclays Boosts Price Target on Ligand Pharmaceutica..
MT
09/16LIGAND PHARMACEUTICALS INCORPORATED : September Corporate Presentation
PU
09/15LIGAND PHARMACEUTICALS INCORPORATED : H.C. Wainwright Investor Conference
PU
09/14LIGAND PHARMACEUTICALS INCORPORATED : September Corporate Presentation
PU
09/09LIGAND PHARMACEUTICALS INCORPORATED : September Investor Roadshow
PU
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) dropped from S&P 400 Health Care
CI
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) dropped from S&P 400
CI
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) dropped from S&P 400 - Biotechnology
CI
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) added to S&P 600
CI
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) added to S&P 600 Health Care
CI
More news
Analyst Recommendations on LIGAND PHARMACEUTICALS INCORPORATED
More recommendations
Financials (USD)
Sales 2021 270 M - -
Net income 2021 67,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 32,2x
Yield 2021 -
Capitalization 2 172 M 2 172 M -
Capi. / Sales 2021 8,05x
Capi. / Sales 2022 11,7x
Nbr of Employees 155
Free-Float 95,2%
Chart LIGAND PHARMACEUTICALS INCORPORATED
Duration : Period :
Ligand Pharmaceuticals Incorporated Technical Analysis Chart | LGND | US53220K5048 | MarketScreener
Technical analysis trends LIGAND PHARMACEUTICALS INCORPORATED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 130,26 $
Average target price 207,86 $
Spread / Average Target 59,6%
EPS Revisions
Managers and Directors
John L. Higgins Chief Executive Officer & Director
Matthew William Foehr President & Chief Operating Officer
Matthew Edward Korenberg Chief Financial Officer & Executive VP-Finance
John W. Kozarich Chairman
Eric Vajda Vice President-Preclinical Research & Development
Sector and Competitors
1st jan.Capi. (M$)
LIGAND PHARMACEUTICALS INCORPORATED30.98%2 172
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414